Clinical Trial Update: A Study of AZD2014 in Combination With Selumetinib in Patients With Advanced Cancers [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 trial evaluating AZD2014 in combination with selumetinib in advanced cancers, including triple-negative breast cancer and squamous cell lung cancer,…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-squamous Cell Lung Cancer with Kras Mutations
• Non-squamous Cell Lung Cancer with Wild-type Kras
• Squamous Cell Lung Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• AZD2014 (vistusertib)
• Selumetinib (selumetinib)

Snippet

Sponsor: Queen Mary University of London | Conditions: Triple-Negative Breast Cancer, Squamous Cell Lung Cancer | Phase 1, Phase 2 | Status: UNKNOWN